Aliases & Classifications for Glioma

MalaCards integrated aliases for Glioma:

Name: Glioma 53 37 29 55 73

Classifications:



External Ids:

KEGG 37 H00042
UMLS 73 C0017638

Summaries for Glioma

NIH Rare Diseases : 53 Glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. It is generally classified based on which type of glial cell is involved in the tumor: Astocytoma - tumors that develop from star-shaped glial cells called astrocytes Ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord Oligodendrogliomas - tumors that affect the oligodendrocytes The symptoms of glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. The exact underlying cause is unknown. In most cases, the tumor occurs sporadically in people with no family history of the condition. Treatment depends on many factors, including the type, size, stage and location of the tumor, but may include surgery, radiation therapy, chemotherapy and/or targeted therapy.

MalaCards based summary : Glioma is related to malignant glioma and astrocytoma. An important gene associated with Glioma is MIR21 (MicroRNA 21
Pretreatment of glioma cells with locked nucleic acid (LNA)-antimiR-21 molecules leads to synergistic antitumor efficacy both in vitro and in vivo.), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial.

Wikipedia : 76 A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise... more...

Related Diseases for Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 malignant glioma 34.7 CDKN2B-AS1 H19 HOXA11-AS MALAT1 MEG3
2 astrocytoma 33.5 H19 HOTAIR MIR21 NEAT1
3 retinoblastoma 33.1 HOTAIR MALAT1 MEG3 MIR34A
4 neuroblastoma 31.8 H19 HOTAIR MALAT1 MEG3 MIR184 MIR221
5 glioblastoma 31.3 H19 HOTAIR MALAT1 MEG3 MIR181A2 MIR21
6 medulloblastoma 31.2 CDKN2B-AS1 H19 HOTAIR MIR17 MIR34A
7 pituitary adenoma 31.1 H19 HOTAIR MALAT1 MEG3
8 melanoma 31.0 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR181A2
9 small cell cancer of the lung 30.9 HOTAIR MALAT1 MIR21
10 lung cancer susceptibility 3 30.8 H19 HOTAIR MALAT1 MEG3
11 squamous cell carcinoma 30.7 CDKN2B-AS1 H19 HOTAIR MALAT1 NEAT1
12 diffuse large b-cell lymphoma 30.7 HOTAIR MIR21 MIR221
13 b-cell lymphomas 30.4 HOTAIR MALAT1 MIR17
14 nasopharyngeal carcinoma 30.4 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 NEAT1
15 osteogenic sarcoma 30.3 CDKN2B-AS1 H19 HOTAIR HOXA11-AS MALAT1 MEG3
16 systemic lupus erythematosus 30.3 MALAT1 MIR15B MIR184 MIR296 NEAT1
17 leukemia, acute myeloid 30.2 CDKN2B-AS1 HOTAIR MALAT1 MEG3 MIR15B MIR181A2
18 lung cancer 30.1 CDKN2B-AS1 H19 HOTAIR HOXA11-AS MALAT1 MEG3
19 hepatocellular carcinoma 30.0 CDKN2B-AS1 H19 HOTAIR HOXA11-AS MALAT1 MEG3
20 gastric cancer 30.0 CDKN2B-AS1 H19 HOTAIR HOXA11-AS MALAT1 MEG3
21 pancreatic cancer 30.0 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 MIR15B
22 breast cancer 29.9 CDKN2B-AS1 FOXO1 H19 HOTAIR HOXA11-AS MALAT1
23 thyroid cancer, nonmedullary, 1 29.9 H19 HOTAIR MALAT1 MEG3 MIR146B MIR181A2
24 ovarian cancer 29.7 CDKN2B-AS1 H19 HOTAIR HOXA11-AS MALAT1 MEG3
25 prostate cancer 29.6 CDKN2B-AS1 FOXO1 H19 HOTAIR MALAT1 MEG3
26 glioma susceptibility 1 12.4
27 optic nerve glioma 12.3
28 brain stem glioma 12.3
29 diffuse intrinsic pontine glioma 12.3
30 childhood brain stem glioma 12.2
31 optic pathway glioma 12.2
32 glioma susceptibility 2 12.2
33 glioma susceptibility 3 12.1
34 glioma susceptibility 9 12.1
35 brain glioma 12.1
36 mixed glioma 12.1
37 third ventricle chordoid glioma 12.0
38 chordoid glioma 12.0
39 subependymal glioma 12.0
40 spinal cord glioma 12.0
41 childhood optic nerve glioma 12.0
42 angiocentric glioma 12.0
43 glioma susceptibility 4 11.8
44 glioma susceptibility 6 11.8
45 glioma susceptibility 8 11.8
46 adult brain stem glioma 11.8
47 adult brainstem mixed glioma 11.8
48 glioma susceptibility 5 11.8
49 glioma susceptibility 7 11.8
50 visual pathway and hypothalamic glioma, childhood 11.7

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma

Symptoms & Phenotypes for Glioma

Drugs & Therapeutics for Glioma

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 660)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 498142 38904
5
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
8
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
9
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
11
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
12 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
13
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
14
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
16
Dabrafenib Approved, Investigational Phase 4,Phase 2,Phase 1 1195765-45-7 44462760 44516822
17
Trametinib Approved Phase 4,Phase 2,Phase 1 871700-17-3 11707110
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
20
Glutamic Acid Approved, Nutraceutical Phase 4,Not Applicable 56-86-0 33032
21 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
22
Lactitol Investigational Phase 4,Phase 2,Phase 1 585-86-4 3871
23 Etiracetam Investigational Phase 4,Phase 1,Phase 2 33996-58-6
24 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
28 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
34 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
38 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
39 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Neuroprotective Agents Phase 4,Phase 2,Phase 1
48 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Anti-Anxiety Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2071)
# Name Status NCT ID Phase Drugs
1 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
2 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
3 Seizure Treatment in Glioma Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
5 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
7 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
8 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
9 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
10 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
11 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
12 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
13 Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Unknown status NCT01878266 Phase 3
14 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
15 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
16 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
17 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
18 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
19 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
20 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
21 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
22 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
23 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
24 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
25 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
26 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
27 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
28 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
29 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
30 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
31 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
32 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
33 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
34 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
35 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
36 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
37 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
38 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
39 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
40 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
41 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
42 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
43 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
44 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
45 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
46 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
47 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
48 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
49 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
50 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo

Search NIH Clinical Center for Glioma

Genetic Tests for Glioma

Genetic tests related to Glioma:

# Genetic test Affiliating Genes
1 Glioma 29

Anatomical Context for Glioma

MalaCards organs/tissues related to Glioma:

41
Brain, T Cells, Endothelial, Spinal Cord, Bone, Testes, Bone Marrow

Publications for Glioma

Articles related to Glioma:

(show top 50) (show all 7189)
# Title Authors Year
1
Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. ( 29441040 )
2018
2
Progressive optic nerve glioma: orbital biopsy technique using a surgical navigation system. ( 29426453 )
2018
3
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. ( 29666296 )
2018
4
Long non-coding RNA ENST01108 promotes carcinogenesis of glioma by acting as a molecular sponge to modulate miR-489. ( 29421578 )
2018
5
IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. ( 29414139 )
2018
6
Staged Image-guided Robotic Radiosurgery and Deferred Chemotherapy to Treat a Malignant Glioma During and After Pregnancy. ( 29632751 )
2018
7
Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. ( 29571074 )
2018
8
Sinomenine Induces G1-Phase Cell Cycle Arrest and Apoptosis in Malignant Glioma Cells Via Downregulation of Sirtuin 1 and Induction of p53 Acetylation. ( 29756546 )
2018
9
Prevalence of human immunodeficiency virus infection in brain glioma patients: Is the virus protective from gliomas? ( 29930869 )
2018
10
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade. ( 29731795 )
2018
11
MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma. ( 29969628 )
2018
12
Hyperbaric oxygen inhibits production of CD3+ T cells in the thymus and facilitates malignant glioma cell growth. ( 29785863 )
2018
13
Prognostic significance of epidermal growth factor receptor expression in glioma patients. ( 29445288 )
2018
14
Expression and functional analysis of TCF4 isoforms in human glioma cells. ( 29436621 )
2018
15
The long non-coding RNA <i>HOTAIR</i> is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. ( 29644006 )
2018
16
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. ( 29746225 )
2018
17
CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. ( 29904623 )
2018
18
Corrigendum: Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. ( 29897054 )
2018
19
Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. ( 29063425 )
2018
20
End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective. ( 29966347 )
2018
21
Isolated Optic Nerve Glioma in Children With and Without Neurofibromatosis: Retrospective Characterization and Analysis of Outcomes. ( 29502465 )
2018
22
Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma. ( 29963235 )
2018
23
ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. ( 29017962 )
2018
24
Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas. ( 29746652 )
2018
25
IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. ( 29621254 )
2018
26
Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis. ( 29288860 )
2018
27
Delineation of the visual pathway in paediatric optic pathway glioma patients using probabilistic tractography, and correlations with visual acuity. ( 29527480 )
2018
28
Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. ( 29704429 )
2018
29
Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells. ( 29434995 )
2018
30
Snail regulates BMP and TGFI^ pathways to control the differentiation status of glioma-initiating cells. ( 29449696 )
2018
31
MicroRNA-599 suppresses glioma progression by targeting RAB27B. ( 29963197 )
2018
32
Immunotherapies for malignant glioma. ( 29242608 )
2018
33
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
34
GBP3 promotes glioma cell proliferation via SQSTM1/p62-ERK1/2 axis. ( 29128363 )
2018
35
Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. ( 28903484 )
2018
36
GLUT5 increases fructose utilization and promotes tumor progression in glioma. ( 29660339 )
2018
37
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma. ( 29805628 )
2018
38
Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma. ( 29343959 )
2018
39
A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. ( 29476136 )
2018
40
Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel. ( 29970574 )
2018
41
I^-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells. ( 28776671 )
2018
42
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. ( 29404979 )
2018
43
Combination therapy of intravenously injected microglia and radiotherapy prolongs survival in a rat model of spontaneous malignant glioma. ( 29928947 )
2018
44
Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. ( 29143923 )
2018
45
The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective. ( 29868485 )
2018
46
Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma. ( 29689474 )
2018
47
Repression of the expression of PPP3CC by ZEB1 confers activation of NF-I_B and contributes to invasion and growth in glioma cells. ( 29294030 )
2018
48
5-ALA in the management of malignant glioma. ( 29737540 )
2018
49
Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats. ( 29658349 )
2018
50
Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2. ( 29436609 )
2018

Variations for Glioma

Copy number variations for Glioma from CNVD:

7 (show top 50) (show all 1065)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion BC037540 Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma

Expression for Glioma

Search GEO for disease gene expression data for Glioma.

Pathways for Glioma

Pathways related to Glioma according to KEGG:

37
# Name Kegg Source Accession
1 Glioma hsa05214
2 MicroRNAs in cancer hsa05206

Pathways related to Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MIR15B MIR17 MIR181A2 MIR21 MIR221 MIR222
2 11.03 MIR15B MIR221 MIR222
3 10.84 MIR146B MIR181A2 MIR221 MIR222
4 10.34 HOTAIR MEG3

GO Terms for Glioma

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.92 FOXO1 MIR15B MIR21 MIR221
2 positive regulation of protein kinase B signaling GO:0051897 9.81 MIR21 MIR221 MIR222
3 negative regulation of angiogenesis GO:0016525 9.71 MIR15B MIR21 MIR222 MIR34A
4 positive regulation of epithelial to mesenchymal transition GO:0010718 9.67 MIR21 MIR221 MIR222
5 positive regulation of erythrocyte differentiation GO:0045648 9.64 MIR221 MIR222
6 negative regulation of vascular endothelial cell proliferation GO:1905563 9.63 MIR15B MIR34A
7 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.63 MIR15B MIR222
8 negative regulation of sprouting angiogenesis GO:1903671 9.63 MIR17 MIR221 MIR34A
9 regulation of reactive oxygen species metabolic process GO:2000377 9.62 FOXO1 MIR21
10 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.61 MIR21 MIR221
11 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR21 MIR34A
12 positive regulation of endothelial cell differentiation GO:0045603 9.6 MIR181A2 MIR21
13 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.59 MIR17 MIR34A
14 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.58 MIR221 MIR222
15 positive regulation of connective tissue replacement GO:1905205 9.58 MIR15B MIR34A
16 positive regulation of metalloendopeptidase activity GO:1904685 9.57 MIR17 MIR21
17 negative regulation of vascular smooth muscle cell differentiation GO:1905064 9.56 MIR15B MIR221
18 positive regulation of axon regeneration GO:0048680 9.55 MIR221 MIR222
19 negative regulation by host of viral genome replication GO:0044828 9.54 MIR221 MIR222
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR17 MIR21
21 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.51 MIR221 MIR222
22 negative regulation of cell adhesion molecule production GO:0060354 9.48 MIR221 MIR222
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 MIR17 MIR21 MIR221 MIR222
24 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.43 MIR221 MIR222
25 miRNA mediated inhibition of translation GO:0035278 9.43 MIR15B MIR17 MIR181A2 MIR21 MIR221 MIR222
26 positive regulation of Schwann cell migration GO:1900149 9.37 MIR221 MIR222
27 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.32 MIR221 MIR222
28 gene silencing by miRNA GO:0035195 9.28 MIR146B MIR15B MIR17 MIR181A2 MIR21 MIR221
29 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.26 MIR221 MIR222

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR146B MIR15B MIR17 MIR181A2 MIR21 MIR221

Sources for Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....